ESMO 2022 | Decipher genomic classifier prognostically stratifies patient with PC treated with abiraterone

Marina Parry, PhD, University College London, London, UK, provides an overview of the Phase III STAMPEDE (NCT00268476) trial on the clinical qualification of transcriptome signatures for advanced prostate cancer starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone. The benefit of abiraterone was consistent, suggesting abiraterone was effective for all patients. However, as the outcomes were variable, when assessing the prognostic associations when patients were classified as either metastatic or non-metastatic according to decipher genomic classifier, patients with a higher decipher score, regardless of treatment with abiraterone or ADT, fared worse than patients who had a decipher score above the median. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.